Shopping Cart
- Remove All
- Your shopping cart is currently empty
LCS3 is a reversible and non-competitive synergistic inhibitor of glutathione disulfide reductase (GSR) and thioredoxin reductase 1 (TXNRD1) with IC50s of 3.3 μM and 3.8 μM, respectively. LCS3 has antitumour activity, induces apoptosis and can be used in the study of lung adenocarcinoma (LUAD).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $51 | In Stock | |
5 mg | $122 | In Stock | |
10 mg | $197 | In Stock | |
25 mg | $455 | In Stock | |
50 mg | $672 | In Stock | |
100 mg | $956 | In Stock | |
500 mg | $1,920 | In Stock |
Description | LCS3 is a reversible and non-competitive synergistic inhibitor of glutathione disulfide reductase (GSR) and thioredoxin reductase 1 (TXNRD1) with IC50s of 3.3 μM and 3.8 μM, respectively. LCS3 has antitumour activity, induces apoptosis and can be used in the study of lung adenocarcinoma (LUAD). |
Targets&IC50 | GSR:3.3 µM, TXNRD1:3.8 µM, M. tuberculosis:0.098 µM(MIC) |
In vitro | LCS3 (5 nM-10 µM ; 96 h) effectively inhibits lung cancer cell lines, while non-transformed lung cells show no signs of inhibition.[1] LCS3 (3 µM ; 3, 6, and 12 h) induces ROS and NRF2 pathway activation in sensitive lung adenocarcinoma (LUAD) cells.[1] LCS3 (3 µM ; 96 h) selectively kills lung adenocarcinoma (LUAD) cell lines, in part through the induction of apoptosis.[1] |
Molecular Weight | 266.64 |
Formula | C11H7ClN2O4 |
Cas No. | 109844-92-0 |
Storage | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 112.5 mg/mL (421.9 mM), Sonication and heating to 60℃ are recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.